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Background: The optimal success of bactericidal therapy
against Enterococcal infections currently relies on the use of the
synergistic combination of a cell wall-active agent, a penicillin or a
glycopeptide, with an aminoglycoside (gentamicin/streptomycin).
Nonetheless, the acquisition of ribosomalmutations and/or amino-
glycosidemodifying enzymes (AGMEs) had led to the emergence of
high-Level aminoglycoside resistant strains that pose a signiﬁcant
therapeutic challenge. Hence, the study was aimed to detect the
incidence of HLAR among the non-urinary Enterococcal isolates.
Methods & Materials: Twenty six non-urinary isolates of Ente-
rococcus species (E. faecalis (n =15), E. facium (n =5), Enterococcus
spp (n=6)) isolated frompus (n=20), ﬂuids (n =5) and blood (n=1)
were included in the study. Susceptibility to vancomycin (30g),
teicoplanin(30g), linezolid(30g), gentamicin(120g), strepto-
mycin(300g) and screening for HLAR was performed as per CLSI,
2015. Molecular detection of the genes encoding vancomycin,
aminoglycoside resistance viz.,vanA, vanB, aac(6′)-Ie–aph(2′′)-Ia,
aph(2′′)-Ib, aph(2′′)-Ic, aph(2′′)-Id, aph(3′′)-IIIa and ant(4′)-Ia was
carried out by multiplex PCR.
Results: High-level resistance to gentamicin and streptomycin
(HLGR HLSR) was observed in 14 (53.8%) isolates while, 6(23.1%),
2(7.7%) isolates exhibited HLGR HLSS and HLGS HLSR phenotype
respectively. MIC of gentamicin and streptomycin of the HLGR,
HLSR isolates was found to be > 500g/ml and >2000g/ml
respectively. aac(6′)-Ie–aph(2′′)-Ia and aph(3′′)-IIIa were detected
in 5(22.7%) and 1(4.5%) of the HLAR isolates respectively while,
9(40.9%) of the HLAR isolates harboured both aac(6′)-Ie–aph(2′′)-
Ia and aph(3′′)-IIIa. None of the isolates exhibited resistance
to teicoplanin and linezolid. Nevertheless, one isolate exhibited
intermediate resistance to vancomycin by disc diffusion but was
conﬁrmed to be susceptible by E-test and did not harbour vanA and
vanB.
Conclusion: Aminoglycosides are the most frequently pre-
scribed antibiotics in clinical practice as they possess good
pharmacokinetics and exhibit synergism with beta-lactams and
glycopeptides. However, we report an increased incidence of HLAR
among the non-urinary Enterococcal isolates. This is indicative of
an increased dissemination of aminoglycoside resistance genes in
our geographical setting. Hence, prompt detection and characteri-
zation of HLAR strains is essential as these have lost synergismwith
the cell wall active agents. Also, absence of VRE could be attributed
to the restricted usage of vancomycin in our setting.
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Background: Antibiotic resistance is a major global health
threat. Owing to the multiplicity of bacterial pathogens and drugs
to treat them, quantifying the overall status of antibiotic effec-
tiveness or resistance is challenging. We used the Drug Resistance
Index (DRI), a novel metric which aggregates antibiotic consump-
tion and resistance into a single measure, to compare antibiotic
effectiveness by country and time.
Methods & Materials: Adapting the methodology described
by Laxminarayan and Klugman (2011), we calculated annual
DRIs for 30 countries. Our index includes six common bacte-
rial pathogens and antibiotic classes used for their treatment.
The pathogens included are: Escherichia coli, Klebsiella pneu-
moniae, Pseudomonas aeruginosa, Staphylococcus aureus, Entero-
coccus faecium, and Enterococcus faecalis. The antibiotic classes
are: aminoglycosides, broad-spectrum penicillins, carbapenems,
cephalosporins, narrow-spectrum penicillins, and quinolones.
Antibiotic use frequencies were obtained from IMS Health. Data
on antibiotic resistance were obtained from ResistanceMap (resis-
tancemap.cddep.org). To calculate the index,weﬁrstmultiplied the
frequency of use of each antibiotic class by the aggregated resis-
tance rates of pathogens against which the antibiotic class is used.
Then, we summed the weighted resistances to each antibiotic class
and generated DRI values.
Results: We present the DRI values as ranging between 0 and
100,where 0 representsmaximumantibiotic effectiveness and 100
indicates no effectiveness of antibiotics. In 2010, among 29 coun-
tries, the highest DRIs were observed for India (74.4), Greece (45.5)
and Portugal (43.4), while the countries with the lowest DRIs were
Sweden (3.0), Denmark (8.2) andNorway (8.5). Among the18 coun-
tries for which data were available to calculate DRIs for the entire
2000-2010 period, increases in DRIswere observed in 15 countries.
Czech Republic had the greatest increase of 24.6 points (4.0 in 2000
to 28.6 in 2010). The United Kingdom had the greatest decline of
10.3 points (42.0 in 2000 to 31.7 in 2010). Across these 18 countries,
the DRIs increased by an average of 7.2 points during 2000-2010,
implying that the overall effectiveness of antibiotics declined.
Conclusion: The DRI can be a valuable tool to quantify, track
and compare antibiotic effectiveness worldwide.
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